Urological Center, Bangkok General Hospital, Bangkok, Thailand.
J Sex Med. 2010 Sep;7(9):3115-26. doi: 10.1111/j.1743-6109.2010.01743.x.
Benign prostatic hyperplasia (BPH) is a common condition among elderly men. The aim of therapy is to improve lower urinary tract symptoms (LUTS) and quality of life (QoL) and to prevent complications.
The primary objective was to assess the effect on ejaculatory dysfunction (EjD) of 6 months treatment with alfuzosin (XATRAL) 10 mg once daily (OD) in men with LUTS suggestive of BPH in Thailand. Secondary objectives were to evaluate the efficacy of alfuzosin on LUTS, bother score (International Prostate Symptom Score [IPSS] 8th question), erectile dysfunction (ED), onset of action, and tolerability.
Overall, 99 men with moderate to severe LUTS suggestive of BPH (mean IPSS 18.9, bother score 4.3) were enrolled in an open-label study. Sexual function was evaluated at baseline and after 6 months treatment, using the International Index of Erectile Function-5 and the Male Sexual Health Questionnaire (MSHQ) ejaculation score, a new validated questionnaire assessing seven EjD symptoms.
The main outcome measure is mean change from baseline to the end of treatment in the MSHQ Ejaculation score.
MHSQ ejaculation score significantly improved from 23.09 at baseline to 21.54 at 6 months (P=0.022). Overall, 70% of patients perceived an improvement in LUTS within 1 week (36.3% within 3 days). IPSS total score significantly improved from 18.93 at baseline to 9.59 at 6 months (P<0.001). IPSS voiding and irritative subscores also significantly improved. The percentage of patients with moderate or severe ED decreased from 35.3% at baseline to 21.8% at 6 months. Most adverse events were dizziness (3%) and orthostatic hypotension (1%) with minor intensity. No significant change in blood pressure and heart rate was observed.
Alfuzosin 10 mg OD administered for 6 months provides a marked and rapid (within 1 week) improvement in LUTS and bother score while improving both ED and EjD.
良性前列腺增生（BPH）是老年男性的常见病症。治疗的目的是改善下尿路症状（LUTS）和生活质量（QoL），并预防并发症。
主要目的是评估 6 个月的阿夫唑嗪（XATRAL）治疗对泰国患有提示 BPH 的 LUTS 男性射精功能障碍（EjD）的影响。次要目的是评估阿夫唑嗪对 LUTS、困扰评分（国际前列腺症状评分[IPSS]第 8 个问题）、勃起功能障碍（ED）、起效时间和耐受性的疗效。
共有 99 名患有中度至重度提示 BPH 的 LUTS 的男性（平均 IPSS 18.9，困扰评分 4.3）参加了一项开放性研究。使用国际勃起功能指数-5 和男性性健康问卷（MSHQ）射精评分，这是一种新的评估七种 EjD 症状的验证问卷，在基线和 6 个月治疗后评估性功能。
主要观察指标是 MSHQ 射精评分从基线到治疗结束的平均变化。
MSHQ 射精评分从基线的 23.09 显著改善至 6 个月的 21.54（P=0.022）。总体而言，70%的患者在 1 周内（36.3%在 3 天内）感知到 LUTS 的改善。IPSS 总分从基线的 18.93 显著改善至 6 个月的 9.59（P<0.001）。IPSS 排尿和刺激子评分也显著改善。中度或重度 ED 的患者百分比从基线的 35.3%下降至 6 个月的 21.8%。大多数不良事件为头晕（3%）和体位性低血压（1%），强度较轻。未观察到血压和心率的显著变化。
阿夫唑嗪 10mg 每日一次给药 6 个月可显著且迅速（1 周内）改善 LUTS 和困扰评分，同时改善 ED 和 EjD。
